Court clears acquisition of Dendreon by Valeant

After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain available to prostate cancer patients. Whether Valeant will actually invest in the further development of sipuleucel-T is unknown at this time.

Valeant to acquire assets of Dendreon

According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there were no other qualified bidders that sought to compete with Valeant for these assets. Court approval of the sale will be sought on February 20.

The optimization of risk assessment for management of prostate cancer

According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of strategies for assessing prostate cancer risk and subsequent treatment, when this is needed. … READ MORE …

Boxer, Sessions re-introduce National Prostate Cancer Action Plan Act

Last Wednesday (January 21), Senators Barbara Boxer (D, CA) and Jeff Sessions (R, AL) re-introduced the National Prostate Cancer Plan Act — a piece of legislation that they had previously introduced during the 113th Congress. … READ MORE …

How do cancer cells that only absorb a sub-lethal dose of radiation get destroyed by the immune system?

A recent commentary on combined radiation and immune therapy included the following statement without further explanation: “Radiation-modified cancer cells that escaped direct annihilation become more immune-susceptible too.” … READ MORE …

Bill Manning’s blog: Part IX

Here is the latest of Bill’s blog posts. It seems that Bill’s benefits — to any meaningful extent — from drugs like abiraterone and enzalutamide are over. He, and we, hope it will be helpful to all those battling late stage prostate cancer. Click here for earlier parts if you missed them. … READ MORE …

Ageism in prostate cancer treatment

We’ve all heard the age-related treatment recommendations of doctors. … READ MORE …


Get every new post delivered to your Inbox.

Join 1,241 other followers